Anti CYLD
Home Up Anti C CRP, Rat & Dog ELISA Kit C1q Cachectic Factor Calbindin Calcineurin A and B Calcitonin CaSR C28R2 Calcium Transporters Calretinin Calsarcin/Myozenin THC & THC ELISA Kits Capsaicin Receptor CPT-1 & CPT-2 CDMP CART CBFA-1 CGRP CHIP/CHIP29 Chloride Channel Clock D Presursor/Adipsin Connexin 26 Core Binding Factor CRT CRY1 and CRY2 CUGBP2 CNG1, CNG2, CNG3, CNG4 or CNG beta Cyclooxygenase Cytochrome C Cytochrome P450 Anti CYLD

 

Cylindromatosis (CYLD) polyclonal antibody
 
Cat. No. Format Size
PAB11624 Purified 100 µg
Animal ID: 
RB0275-0276 
 
Host: 
Rabbit 
 
Reactivity: 
human 
 
Buffers: 
Purified rabbit polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column and eluted out with both high and low pH buffers and neutralized immediately after elution then followed by dialysis against PBS. 
 
Storage: 
Maintain refrigerated at 2-8ºC for up to 6 months. For long term storage store at -20ºC. Avoid repeated freeze-thaw cycles. 
 
Application: 
Tested by peptide-specific ELISA (1:1,000). 
 
Immunogen:
KLH conjugated synthetic peptide comprised of amino acids 1 - 15 [MSSGLWSQEKVTSPY] of the human cylindromatosis (CYLD) protein. 
Accession number:
NM_015247 
Description:
The cylindromatosis (CYLD) protein is 956 amino acids long and has been implicated in cylindromatosis (Turban Tumor Syndrome) and may also play a role in oncogenesis. Germline Mutations in the CYLD cause cylindromas: benign adnexal skin tumors often found in the scalp area. In most cases the second wild-type allele is lost in tumor tissue, suggesting that CYLD functions as tumor suppressor. It has been demonstrated that inhibition of CYLD enhances activation of NF-kappaB; inhibition of CYLD also increases resistance to apoptosis, suggesting a mechanism through which loss of CYLD contributes to oncogenesis.
Alternative Name(s):
Turban tumor syndrome protein, cylindromatosis protein, EAC, CDMT, CYLD1, HSPC057, KIAA0849, Brooke¿Spiegler syndrome protein, BSS, familial cylindromatosis protein 
References:
 
  1. Regamey A, Hohl D, Liu JW, Roger T, Kogerman P, Toftgard R, Huber M: The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor.J. Exp. Med. 198(12): 1959-1964 (2003).
  2. Hu G, Onder M, Gill M, Aksakal B, Oztas M, Gurer MA, Celebi JT: A novel missense mutation in CYLD in a family with Brooke-Spiegler syndrome.J. Invest. Dermatol. 121(4): 732-734 (2003).
  3. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G: The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination.Nature 424(6950): 801-805 (2003).